BTG PLC (BTG.L)

BTG.L on London Stock Exchange

734.50GBp
3:58am EDT
Change (% chg)

0.50p (+0.07%)
Prev Close
734.00p
Open
730.50p
Day's High
735.00p
Day's Low
726.50p
Volume
64,385
Avg. Vol
674,865
52-wk High
835.87p
52-wk Low
508.50p

BTG.L

Chart for BTG.L

About

BTG plc is a United Kingdom-based specialist healthcare company focused on developing and commercializing products targeting acute care, cancer and vascular diseases. The Company operates in three business segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. Its Interventional Medicines include Interventio... (more)

Overall

Beta: 0.39
Market Cap(Mil.): £2,771.70
Shares Outstanding(Mil.): 381.78
Dividend: --
Yield (%): --

Financials

  BTG.L Industry Sector
P/E (TTM): 66.76 39.17 40.23
EPS (TTM): 0.11 -- --
ROI: 6.13 15.86 15.26
ROE: 7.14 16.36 16.08
Search Stocks

British drugs firm BTG lifts 2014/15 sales forecast

LONDON, April 2 - British drugs company BTG nudged up its 2014/15 revenue forecast on Thursday and said it was on course for further strong growth in its new financial year.

02 Apr 2015

BRIEF-Britihs pharma co BTG launches ADR programme

* Adr programme will be open for deposits from 9 a.m. (est) today Source text for Eikon: Further company coverage:

19 Feb 2015

British drugs company BTG lifts revenue guidance

LONDON - British drugs company BTG lifted its forecast for annual revenues by as much as 4 percent on Thursday, citing the benefits of a U.S. acquisition and the reversal of currency headwinds.

05 Feb 2015

British drugs company BTG lifts revenue guidance

LONDON, Feb 5 - British drugs company BTG lifted its forecast for annual revenues by as much as 4 percent on Thursday, citing the benefits of a U.S. acquisition and the reversal of currency headwinds.

05 Feb 2015

BRIEF-BTG raises full-year revenue forecast

* Full year revenue is now expected to be in range 345 mln-360 mln stg; previous guidance was 330 mln-345 mln stg

05 Feb 2015

BRIEF-BTG raises about 150 mln stg by placing new shares

* Placing raised proceeds of approximately 150 mln stg (before expenses)

04 Dec 2014

CORRECTED-BRIEF-BTG to acquire Pneumrx for up to $475 mln, funded by placing

* Announce that it has entered into an agreement to acquire pneumrx inc on a debt free cash free basis for an initial cash consideration of us$230 million

04 Dec 2014

BTG to buy lung intervention firm for up to $475 mln

LONDON, Dec 4 - BTG, the healthcare group best known for treating rattlesnake bites and varicose veins, is expanding into lung care by buying a Californian firm that has developed a device to prop open airways.

04 Dec 2014

BTG says long-awaited varicose vein treatment has positive debut

Nov 11 - British drugs company BTG said it had started to roll out its varicose vein treatment to a positive response in the United States, as it said revenue for the year would be at the top end of forecasts.

11 Nov 2014

BRIEF-BTG posts rise in H1 profit, sees full-year revenue at top end

* Operating profit increased to £42.8m (h1 13/14: £25.0m)

11 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Edison Investment Research
$10.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks